Publication | Open Access

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHematologyClinical TrialsMyeloid NeoplasiaPharmacotherapyIntensive Chemotherapy10-Day DecitabineOncologyRadiation OncologyHealth Sciences